Apple stock at $333.02 seen as overvalued by DCF analysis

Apple shares closed at $333.02, a 22.7% gain year‑to‑date and a 56.4% rise over the last twelve months, yet GuruFocus’s discounted cash flow (DCF) models peg the intrinsic value between $165.81 and $187.29, implying a margin of safety of –78% to –101%【2】. The disparity highlights a valuation gap that could shape investor sentiment and market positioning.

DCF valuation methodology

GuruFocus applied a two‑stage DCF model. The earnings‑based approach assumes a 15.2% EPS growth rate for the next ten years, discounted at 11%, followed by a 4% terminal growth rate, also discounted at 11%, arriving at an intrinsic value of $187.29【2】. The free‑cash‑flow (FCF) model uses the same discount rate but yields a lower intrinsic value of $165.81, reinforcing the overvaluation conclusion【2】. Both models rely on current EPS of $8.27 and a 10‑year Treasury rate of 4.64% as inputs.

Market implications

The gap between market price and DCF estimates suggests that investors are pricing Apple’s growth prospects, brand strength, and upcoming product cycles more aggressively than the models predict. Compared with the prior year’s price of roughly $214 (derived from the 56.4% rise to $333.02), the current premium is markedly higher than the intrinsic values, indicating that optimism may be driving the stock beyond fundamentals. Competitors such as Microsoft and Alphabet, whose valuations are often benchmarked against similar DCF analyses, could appear relatively cheaper if Apple’s overvaluation persists.

What to watch

• Apple’s upcoming product announcements in the fall quarter, which could influence earnings expectations.
• The company’s Q3 earnings release, slated for early August, to see if revenue growth aligns with the 15.2% EPS projection.
• Analyst revisions to target prices following the earnings call, especially any adjustments that narrow the valuation gap.

The stark contrast between Apple’s market price and its DCF‑derived intrinsic values raises a key question: will the stock’s momentum sustain the premium, or will a correction align price with the more conservative valuation estimates?